Brainstorm Cell Therapeutics ( (BCLI) ) has released its Q3 earnings. Here is a breakdown of the information Brainstorm Cell Therapeutics presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
BrainStorm Cell Therapeutics Inc. is a pioneering company in the biotechnology sector, focusing on the development of adult stem cell therapies for neurodegenerative diseases. The company’s proprietary NurOwn® platform is designed to deliver targeted biological signals to modulate neuroinflammation and promote neuroprotection.
In its latest earnings report for the third quarter of 2025, BrainStorm Cell Therapeutics announced significant progress in its clinical trials and financial performance. The company is preparing to initiate a Phase 3b study of its lead investigational therapy, NurOwn, for amyotrophic lateral sclerosis (ALS), following clearance from the U.S. FDA. This study aims to provide confirmatory data to support a potential Biologics License Application (BLA).
Key financial highlights from the report include a reduction in net loss, which stood at approximately $2.1 million for the quarter, compared to $2.7 million in the same period last year. The company’s general and administrative expenses also decreased significantly, from $2.0 million in the third quarter of 2024 to $1.1 million in 2025. However, the company’s cash position remains a concern, with cash and cash equivalents totaling only $0.23 million as of September 30, 2025.
Additionally, BrainStorm is advancing its clinical programs with the upcoming Phase 3b ENDURANCE study, expected to enroll around 200 participants. This trial will further assess the long-term safety and efficacy of NurOwn in ALS patients. The company is also engaging with the ALS community, acknowledging a Citizen Petition filed with the FDA, which highlights the ongoing interest in NurOwn’s potential therapeutic benefits.
Looking ahead, BrainStorm Cell Therapeutics remains committed to advancing its clinical programs and stabilizing its financial situation. The management is optimistic about the potential of NurOwn to become a valuable treatment for ALS, pending regulatory approval, and continues to work closely with clinical sites and manufacturing partners to ensure operational readiness.